This approach may enable a quicker response to emerging disease outbreaks, as is evident from the swift pursuit of RNA vaccine candidates for the global SARS-CoV-2 pandemic. Both conventional and self-amplifying RNAs have shown protective immunization in preclinical studies against multiple infectious ...
Vaccinology is shifting toward synthetic RNA platforms which allow for rapid, scalable, and cell-free manufacturing of prophylactic and therapeutic vaccines. The simple development pipeline is based on in vitro transcription of antigen-encoding sequences or immunotherapies as synthetic RNA transcripts, whic...
重磅:自我扩增mRNA(‘self-amplifying’ RNA/saRNA)抗新冠疫苗ARCT-154震撼上市!saRNA可在细胞内自我倍增,也就允许初始接种剂量很小,是常规mRNA疫苗的1/10-1/6,可降低副作用;越来越多研究证明,saRNA不仅用...
Revolutionizing Vaccine Development Rapid response to emerging diseases is critical when developing a vaccine. Long RNA (mRNA and saRNA) is at the forefront of vaccine development. Benefits of saRNA saRNA vaccines can be developed in a fraction of the time it takes to develop a conventional vaccine...
“Previously, we had shown our samRNA vaccine capable of driving potentially broad and durable protection through 12 months across three Phase 1 studies spanning multiple other populations and settings. The new findings announced toda...
Self-amplifying RNA (saRNA) is an extremely promising platform because it can produce more protein for less RNA. We used a sort and sequence approach to identify host cell factors associated with transgene expression from saRNA; the hypothesis was that cells with different expression levels would ...
RNA-based vaccines are an attractive candidate for this role: they are safe, are produced cell free, and can be rapidly generated in response to pathogen emergence. Two RNA vaccine platforms are available: synthetic mRNA molecules encoding only the antigen of interest and self-amplifying RNA (sa...
ARCT-154 consists of a replicon based upon Venezuela equine encephalitis virus in which RNA coding for the virus structural proteins has been replaced with RNA coding for the full-length spike (S) glycoprotein of the SARS-CoV-2 D614G variant, encapsulated in lipid nanoparticles. 100 μg act...
AstraZeneca has entered a strategic, long-term research collaboration with biopharmaceutical firm VaxEquity to discover, develop and commercialise self-amplifying RNA (saRNA) therapeutics platform. AstraZeneca Cambridge Biomedical Campus in Cambridge, England. Credit: AstraZeneca. Subscribe to our email...
a homologous prime boost messenger RNA (mRNA)-based vaccination approach elicited predominantly CD4 T cell responses16,17,18. Cumulatively, previous findings suggest that a successful cancer vaccine should (1) target tumor-specific neoantigens, (2) use highly immunogenic vaccine platform(s), (3) ...